Long-term efficacy of combined phacoemulsification and Hydrus microstent in open-angle glaucoma versus combined-mechanism/primary angle closure glaucoma: a retrospective cohort study.

IF 1.7 4区医学 Q3 OPHTHALMOLOGY

BMC Ophthalmology Pub Date : 2026-05-07 DOI:10.1186/s12886-026-04875-w

Kelly C Nguyen, Eden Ng, Sunee Chansangpetch, Sunita Radhakrishnan, Ngoc Nguyen, Andrew G Iwach, Shan Lin

{"title":"Long-term efficacy of combined phacoemulsification and Hydrus microstent in open-angle glaucoma versus combined-mechanism/primary angle closure glaucoma: a retrospective cohort study.","authors":"Kelly C Nguyen, Eden Ng, Sunee Chansangpetch, Sunita Radhakrishnan, Ngoc Nguyen, Andrew G Iwach, Shan Lin","doi":"10.1186/s12886-026-04875-w","DOIUrl":null,"url":null,"abstract":"Background: Compare the efficacy of combined Hydrus-cataract surgery in open angle glaucoma (OAG) to combined mechanism glaucoma (CMG) and primary angle closure glaucoma (PACG) over 36 months.Methods: A retrospective cohort study of patients with CMG, PACG, or OAG who were treated with 1 or more glaucoma medications prior to surgery. Retrospective review of OAG, CMG, or PACG eyes which underwent combined Hydrus-cataract surgery between Jul 2020-Dec 2021. Regression models were used to evaluate IOP, medication use, success rate (IOP ≤ 18 mmHg without medication) and proportion of medication-free eyes.Results: The CMG/PACG group (n = 39) had significantly higher IOP reduction from baseline to 36-months than the OAG group (n = 34) (OAG, 15.03 ± 2.90 mmHg to 13.44 ± 3.85 mmHg, p = 0.016; CMG/PACG, 15.62 ± 3.10 to 13.21 ± 2.61 mmHg, p = 0.002) (p = 0.021 for difference). Number of medications was significantly reduced in both groups (OAG, 2.44 ± 1.33 to 1.18 ± 1.40, p < 0.001; CMG/PACG, 2.29 ± 1.27 to 0.87 ± 1.08, p < 0.001) (p = 0.882 for difference). CMG/PACG had higher success rate (49% vs. 29%) and more medication-free eyes (49% vs. 35%) than OAG but these were not statistically significant (p = 0.09 and 0.25, respectively).Conclusions: This retrospective study supports the long-term efficacy of combined Hydrus-cataract surgery for CMG/PACG and OAG.","PeriodicalId":9058,"journal":{"name":"BMC Ophthalmology","volume":" ","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12886-026-04875-w","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Compare the efficacy of combined Hydrus-cataract surgery in open angle glaucoma (OAG) to combined mechanism glaucoma (CMG) and primary angle closure glaucoma (PACG) over 36 months.

Methods: A retrospective cohort study of patients with CMG, PACG, or OAG who were treated with 1 or more glaucoma medications prior to surgery. Retrospective review of OAG, CMG, or PACG eyes which underwent combined Hydrus-cataract surgery between Jul 2020-Dec 2021. Regression models were used to evaluate IOP, medication use, success rate (IOP ≤ 18 mmHg without medication) and proportion of medication-free eyes.

Results: The CMG/PACG group (n = 39) had significantly higher IOP reduction from baseline to 36-months than the OAG group (n = 34) (OAG, 15.03 ± 2.90 mmHg to 13.44 ± 3.85 mmHg, p = 0.016; CMG/PACG, 15.62 ± 3.10 to 13.21 ± 2.61 mmHg, p = 0.002) (p = 0.021 for difference). Number of medications was significantly reduced in both groups (OAG, 2.44 ± 1.33 to 1.18 ± 1.40, p < 0.001; CMG/PACG, 2.29 ± 1.27 to 0.87 ± 1.08, p < 0.001) (p = 0.882 for difference). CMG/PACG had higher success rate (49% vs. 29%) and more medication-free eyes (49% vs. 35%) than OAG but these were not statistically significant (p = 0.09 and 0.25, respectively).

Conclusions: This retrospective study supports the long-term efficacy of combined Hydrus-cataract surgery for CMG/PACG and OAG.

查看原文本刊更多论文

联合超声乳化和Hydrus微支架治疗开角型青光眼与联合机制/原发性闭角型青光眼的长期疗效：一项回顾性队列研究

背景：比较水合白内障联合手术治疗开角型青光眼（OAG）与联合机制型青光眼（CMG）和原发性闭角型青光眼（PACG） 36个月的疗效。方法：对术前接受一种或多种青光眼药物治疗的CMG、PACG或OAG患者进行回顾性队列研究。对2020年7月至2021年12月期间接受水合白内障联合手术的OAG、CMG或PACG眼进行回顾性分析。采用回归模型评价IOP、用药情况、成功率（IOP≤18 mmHg未用药）及无用药眼比例。结果：从基线到36个月，CMG/PACG组（n = 39）的IOP降低明显高于OAG组（n = 34）（OAG, 15.03±2.90 mmHg至13.44±3.85 mmHg, p = 0.016; CMG/PACG, 15.62±3.10 mmHg至13.21±2.61 mmHg, p = 0.002）（p = 0.021）。两组患者用药次数均显著减少（OAG为2.44±1.33，p为1.18±1.40,p）。结论：本回顾性研究支持CMG/PACG和OAG联合水合白内障手术的远期疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Ophthalmology OPHTHALMOLOGY-

CiteScore

3.40

自引率

5.00%

发文量

441

审稿时长

6-12 weeks

期刊介绍： BMC Ophthalmology is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of eye disorders, as well as related molecular genetics, pathophysiology, and epidemiology.